首页 Genocea Biosciences(usGNCA)-基本信息

Genocea Biosciences(usGNCA)-基本信息

日报更新时间:

周报更新时间:01-16 11:49

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Genocea Biosciences


简介:Genocea Biosciences, Inc.于2006年8月16日在特拉华州注册成立,它是一家处于临床阶段的生物制药公司,同时主要在马塞诸塞州的坎布里奇市开展业务


电话:1-617-8768191


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Genocea Biosciences公司利用其专利发现平台Anigen Lead Acquisition System(ATLAS)来唤醒患者先前存在的CD4 +和CD8 + T细胞对肿瘤的免疫反应,鉴定抗原包含在旨在通过T细胞(或细胞)免疫应答起作用的疫苗中。Genocea Biosciences主要的免疫肿瘤学项目是GEN-009,一种佐剂化的新抗原肽疫苗候选物,处于临床前阶段,旨在指导患者的免疫系统攻击肿瘤。此外,Genocea Biosciences公司还寻求合作伙伴开发针对肿瘤相关抗原的癌症疫苗和针对由Epstein-Barr病毒引起的癌症的疫苗。

交易日期 交易人 职位 类型 交易份额 价格
2017-07-23 Poole Jonathan Chief Financial Officer Buy 45000 3.09
2017-07-23 Poole Jonathan Chief Financial Officer Sell 45000 6.00
2017-05-18 Siber (George R) Director Buy 11230 2.38
2017-05-18 Siber (George R) Director Buy 11057 2.86
2017-05-18 Siber (George R) Director Buy 22287 6.07
2017-05-17 Siber (George R) Director Buy 31045 6.02
2017-05-17 Siber (George R) Director Buy 19281 2.38
2017-05-17 Siber (George R) Director Buy 10084 1.67
2017-05-17 Siber (George R) Director Buy 1680 2.38
2017-05-09 Poole Jonathan Chief Financial Officer Sell 3500 6.13
2017-05-07 Poole Jonathan Chief Financial Officer Sell 6213 6.51
2017-05-02 Poole Jonathan Chief Financial Officer Buy 7937 --
2017-05-02 Poole Jonathan Chief Financial Officer Buy 23810 --
2016-11-08 Hetherington (Seth V) Officer Buy 5000 2.02
2016-11-07 Hoffman (Eric S) Officer Buy 3000 3.59
2016-11-06 Hoffman (Eric S) Officer Buy 4000 3.41
2016-11-06 Clark (William D) Chief Executive Officer Buy 2800 3.49
2016-11-06 Poole Jonathan Chief Financial Officer Buy 7000 3.34
2016-05-08 Poole Jonathan Chief Financial Officer Buy 4000 3.88
2015-12-15 Clark (William D) Chief Executive Officer Buy 3800 6.45
2015-12-13 Flechtner Jessica Baker Officer Buy 5462 2.02
2015-12-13 Flechtner Jessica Baker Officer Buy 3444 2.02
2015-12-10 Hetherington (Seth V) Officer Buy 5000 2.02
2015-08-31 Flechtner Jessica Baker Officer Sell 2229 11.35
2015-08-31 Flechtner Jessica Baker Officer Buy 2229 2.02

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments Inc 22973 0.09% -42100 -64.70% 2019-07-31
BlackRock Fund Advisors 3000474 1.44% 25094 0.84% 2019-07-31
Polaris Venture Management Co. V,LLC 1968606 1.75% -- -- 2019-03-31
Dafna Capital Management LLC 1989653 1.77% 1989653 -- 2019-03-31
Ghost Tree Capital, LLC 2000000 1.78% -1525000 -43.26% 2019-03-31
Vanguard Investments Australia Ltd 477809 1.83% 353879 285.55% 2019-07-31
Vivo Capital, LLC 7811206 6.95% -368794 -4.51% 2019-03-31
Bvf Inc 7828243 6.96% 2713788 53.06% 2019-03-31
NEA Management Company, LLC 34948269 31.09% 9948269 39.79% 2019-03-31
Vanguard Group Inc 1332451 1.19% 29538 2.27% 2019-03-31
Apo Asset Management GmbH 135853 0.52% 90000 196.28% 2019-07-31
Fosun International Ltd 571028 0.51% 167350 41.46% 2019-03-31
Panagora Asset Management Inc 117632 0.10% 9683 8.97% 2019-03-31
Fidelity Management & Research Company 27417 0.10% -591607 -95.57% 2019-07-31
Northern Trust Investments N A 133717 0.12% -- -- 2019-03-31
Northern Trust Corp 133717 0.12% -- -- 2019-03-31
Reichmuth & Co Integrale Vermogensverwaltung AG 31690 0.12% 21000 196.45% 2019-07-31
Hauck & Aufh 403678 0.19% -- -- 2019-07-31
HighTower Advisors, LLC 347100 0.31% 230000 196.41% 2019-03-31
Renaissance Technologies Corp 426254 0.38% 213698 100.54% 2019-03-31
California Public Employees Retrmnt Sys 60000 0.05% -- -- 2019-03-31
BlackRock Inc 199040 0.18% 1154 0.58% 2018-12-31
Geode Capital Management, LLC 434688 0.39% 217344 100.00% 2018-12-31
DRW Securities, LLC 800911 0.71% 331568 70.65% 2018-12-31
Birchview Capital, LP 189000 0.17% -- -- 2018-09-30
Millennium Management LLC 567989 0.66% -285396 -33.44% 2018-09-30
AXA Investment Managers UK Ltd 571818 0.66% -- -- 2018-12-31
Franklin Advisers, Inc. 1728000 1.99% -1133200 -39.61% 2018-11-30
Tekla Capital Management LLC 3466666 4.00% -- -- 2018-11-30
Alyeska Investment Group, L.P. 1603085 1.85% -231719 -12.63% 2018-06-30
Sunrise Partners LLC 400899 0.46% 400899 -- 2018-06-30
Morgan Stanley - Brokerage Accounts 300349 0.35% 118101 64.80% 2018-06-30
Morgan Stanley & Co Inc 300349 0.35% 118101 64.80% 2018-06-30
BlueCrest Capital Management Ltd. 285662 0.33% 285662 -- 2018-06-30
Fidelity Management and Research Company 427323 0.49% 1800 0.42% 2018-03-31
FMR Inc 484523 0.56% 1800 0.37% 2018-03-31
BlackRock Institutional Trust Company NA 188084 -- -758296 -80.13% 2018-06-30
LMR Partners LLP 204774 -- 204774 -- 2018-06-30
Element Capital Management LLC 233776 -- 233776 -- 2018-06-30
Medical Strategy GmbH 323678 -- 323678 -- 2018-06-30
Vivo Opportunity, LLC 8180000 -- 8180000 -- 2018-01-17
New Enterprise Associates 16, LP 25000000 -- 25000000 -- 2018-01-17
Quinn Opportunity Partners LLC 113100 -- -- -- 2018-03-31
Balyasny Asset Management LLC 138088 -- -80596 -36.86% 2018-03-31
Deutsche Bank AG 214830 -- 154149 254.03% 2018-03-31
TIAA-CREF Investment Management LLC 263874 -- 159800 153.54% 2018-03-31
GSA Capital Partners LLP 234065 -- 170265 266.87% 2018-03-31
State Street Corp 632135 -- 261200 70.42% 2018-03-31
Vassalluzzo Scott J 185636 -- 13500 7.84% 2018-03-31
NorthPointe Capital LLC 786634 -- -36943 -4.49% 2017-12-31
Alphamark Advisors, LLC 291934 -- -12952 -4.25% 2017-12-31
Northern Trust Asset Management 173412 -- -1154 -0.66% 2018-04-30
BNY Mellon Investment Management 72413 -- -327 -0.45% 2017-12-31
Principal Life Insurance Co 116250 -- 22632 24.17% 2016-12-31
Virtu Financial LLC 202900 -- 202900 -- 2017-09-30
Sphera Funds Management Ltd. 490000 -- -- -- 2017-09-30
AllianceBernstein LP 578192 -- -7874 -1.34% 2017-09-30
Bridgeway Capital Management, Inc 151000 -- -- -- 2017-09-30
IPConcept (Luxemburg) SA 63953 -- 13953 27.91% 2017-03-31
Franklin Advisers Inc 2994200 10.46% -- -- 2017-06-30
Principal Global Investors, LLC 218100 0.76% -- -- 2017-06-30
T. Rowe Price Associates, Inc. 35889 0.13% 12030 50.42% 2017-06-30
Johnson & Johnson 1330305 4.73% -101215 -7.07% 2015-12-31
Cvf LLC 1226320 4.36% 7580 0.62% 2015-12-31
Deerfield Management Co 687257 2.42% -- -- 2016-09-30
Rock Springs Capital Management LP 480000 1.69% -- -- 2016-09-30
CVF, LLC 1218740 3.00% 14454256 -- 1999-11-30
Johnson Johnson Development Corporation 1431520 3.00% 16977827 0.10% 1999-11-30
S.R. One, Limited 1971668 3.00% 23383982 0.10% 1999-11-30
Stephen Hoffman, M.D., Ph.D. 1992415 3.00% 23630042 0.10% 1999-11-30
Kevin Bitterman, Ph.D. 2055230 3.00% 24375028 0.10% 1999-11-30
FMR LLC, and related funds 3371523 3.00% 39986263 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
MEDICAL BioHealth 403678 0.19% -- -- 2019-01-31
NT US Market Cap Index Fund - Lending 1354 0.01% -- -- 2019-06-30
Vanguard Total Stock Market Index Fund 477809 1.83% 353879 285.55% 2019-06-30
Vanguard Extended Market Index Fund 243451 0.93% 149517 159.17% 2019-06-30
APO Medical Opportunities 111646 0.43% 76000 213.21% 2019-06-30
RIM Global Bioscience 31690 0.12% 21000 196.45% 2019-06-30
apo Medical Opportunities Institutionell 24207 0.09% 14000 137.16% 2019-06-30
Vanguard Balanced Index Fund 14841 0.06% 10601 250.02% 2019-06-30
Vanguard Instl Total Stock Market Idx Fd 13041 0.05% -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 8382 0.03% -- -- 2019-06-30
NT Ext Equity Market Index Fund - L 6939 0.03% -- -- 2019-06-30
The Vanguard Total Stock Market Index 2235 0.01% 2235 -- 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl 2451 0.01% -- -- 2019-06-30
State Street U.S. Extended Market Index 2512 0.01% -- -- 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 1549 0.01% -- -- 2019-07-30
Fidelity 2597 0.01% 2597 -- 2019-06-30
BlackRock Extended Equity Market 4558 0.02% -7 -0.15% 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 5998 0.02% 436 7.84% 2019-06-30
NT Ext Equity Mkt Idx Fd - DC - NL 5998 0.02% 436 7.84% 2019-06-30
BNYM Mellon SL Mkt Completion Fd 5752 0.01% -14496 -71.59% 2019-03-31
Wells Fargo/SSGA Global Equity Index 5724 0.01% -- -- 2019-03-31
iShares Core S&P US Total Market ETF 1547 0.01% -- -- 2019-05-30
iShares Core Growth ETF Portfolio 1548 0.01% 1 0.06% 2019-05-23
iShares Core MSCI AllCntry Wld exCan ETF 1548 0.01% -- -- 2019-05-23
iShares Core Balanced ETF Portfolio 1548 0.01% 1 0.06% 2019-05-23
BNYM Mellon NSL Market Completion Fund 19608 0.02% 18608 1860.80% 2019-03-31
PHARMA/wHEALTH 32936 0.03% -- -- 2018-07-31
BNYM Mellon SL Market Completion Fund 5752 0.01% -14496 -71.59% 2019-03-31
USAA Extended Market Index Fund 3917 -- -- -- 2019-02-28
NT Quality SCC US Fund - Non-Lending 158 -- -- -- 2018-12-31
NT Quality SCC Global Fund - Non-Lending 158 -- -- -- 2018-12-31
State Street Small/Mid Cap Eq Idx Port -- -- -9900 -100.00% 2018-06-30
SAST SA Small Cap Index Portfolio -- -- -6028 -100.00% 2018-06-30
BNY Mellon Market Completion Fund 1000 -- -5390 -84.35% 2018-12-31
iShares Russell 2000 Growth ETF 684380 0.61% 1180 0.17% 2018-06-21
iShares Micro-Cap ETF 222657 0.20% -- -- 2018-06-21
iShares Russell 2000 Value ETF 127055 0.11% -210 -0.17% 2018-06-21
X Russell 2000 ETF 25663 0.02% -2 -0.01% 2018-06-22
iShares Russell 3000 ETF 15821 0.01% -- -- 2018-06-21
Invesco Russell 2000 Equal Weight ETF 7105 0.01% 592 9.09% 2018-06-24
Invesco Wilshire Micro-Cap ETF 11391 0.01% -- -- 2019-01-31
FCP MEDICAL BioHealth-Trends 403678 0.47% -- -- 2018-10-31
RIM Global CC Bioscience 26780 0.03% -- -- 2018-11-30
AXA 2000 Managed Volatility Portfolio 116872 0.13% -- -- 2018-05-31
Vanguard Russell 2000 Index Fund 85562 0.10% 1331 1.58% 2018-05-31
Fidelity Advisor 64200 0.07% -- -- 2018-03-31
iShares Russell 2000 Small-Cap Index Fd 52290 0.06% -- -- 2018-05-31
VALIC Company I Small Cap Index Fund 45712 0.05% -- -- 2018-05-31
TIAA-CREF Small-Cap Blend 33811 0.04% -- -- 2018-05-31
Pacific Select Fund Small-Cap Index 30909 0.04% -- -- 2018-05-31
Schwab Small Cap Index Fund 168200 0.19% -- -- 2018-05-31
Franklin Biotechnology Discovery Fund 1728000 1.99% -- -- 2017-08-31
Tekla World Healthcare Fund 1333333 1.54% -- -- 2017-12-31
OMI IM GBP AXA Framlington Biotech 571818 0.66% -- -- 2017-09-30
FCP MEDICAL BioHealth 323678 0.37% 323678 -- 2018-06-30
AlphaMark Actively Managed Small Cap ETF 272013 0.31% -- -- 2018-01-17
Strategic Advisers 160000 0.18% 160000 -- 2017-07-31
TEKLA HEALTHCARE OPPORTUNITIES FUND 2133333 2.46% -- -- 2017-12-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 129073 0.15% -- -- 2018-07-31
Vanguard Russell 2000 Growth ETF 84 -- -- -- 2018-07-31
The Vanguard Russell 2000 Growth Index 157 -- -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 1225285 1.41% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 751470 0.87% -- -- 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 69972 0.24% 69972 -- 2017-06-30
Fidelity Spartan 59471 0.07% -- -- 2018-07-31
BlackRock Extended Equity Market K 36218 0.04% 985 2.80% 2018-06-30
BNY Mellon EB DL Mkt Completion 19853 0.02% -- -- 2018-06-30
Meeder Spectrum 17406 0.02% -- -- 2018-08-31
Wilshire Micro-Cap ETF 13751 0.01% -- -- 2018-09-14
BNY Mellon Market Completion Fund UC1 6390 0.01% 5377 530.80% 2018-03-31
ProFunds Small Cap Inv 459 -- -- -- 2018-04-30
ProFunds UltraSmall Cap Inv 1206 -- -126 -9.46% 2018-04-30
USAA Extended Market Index 3917 -- -- -- 2018-07-31
Vanguard Balanced Index Inv 7681 0.01% -- -- 2018-07-31
iShares Core S&P Total US Stock Mkt 9708 0.01% -- -- 2018-09-12
SSgA U.S. Total Market Index Fd Class I 5609 0.02% -366 -6.13% 2017-12-31
ProFunds VP UltraSmall-Cap 333 -- -- -- 2018-03-31
Consulting Group Small-Mid Cap Equity 1818 -- -- -- 2018-05-31
Bridge Builder Small/Mid Cap Growth 20263 0.02% 14282 238.79% 2018-03-31
State Farm Small Cap Index A Legacy 19055 0.02% 11790 162.28% 2018-03-31
State Farm VPT Small Cap Equity Index 12171 0.01% 7584 165.34% 2018-03-31
TIAA-CREF Equity Index Instl 15937 0.02% -- -- 2018-05-31
CREF Equity Index R1 20661 0.02% -- -- 2018-05-31
TIAA-CREF Small-Cap Blend Idx Inst 33811 0.04% -- -- 2018-05-31
VALIC Company I Small Cap Index 45712 0.05% -- -- 2018-05-31
CREF Stock R1 243213 0.29% -- -- 2018-04-30
LVIP SSgA Small Cap Index Std 21300 0.03% -- -- 2018-03-31
AXA 2000 Managed Volatility K 116872 0.13% -- -- 2018-05-31
ATM Small Cap Managed Volatility K 23291 0.03% -- -- 2018-05-31
AXA/Lord Abbett Micro Cap K 14505 0.02% -- -- 2018-05-31
Voya Russell Small Cap Index Port I 29165 0.04% 12209 72.00% 2018-03-31
BNY Mellon EB DL Small Cap SIF 57762 0.07% 41894 264.02% 2018-03-31
Master Small Cap Index 52290 0.06% -- -- 2018-05-31
Vanguard Russell 2000 ETF 85562 0.10% 1331 1.58% 2018-05-31
Schwab Small Cap Index 168200 0.19% -- -- 2018-05-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 174688 0.20% 1277 0.74% 2018-05-31
Northern Small Cap Index 42536 0.05% 25538 150.24% 2018-03-31
BlackRock Russell 2500 40109 0.05% 33179 478.77% 2018-03-31
BlackRock Russell 2000 127957 0.15% 86389 207.83% 2018-03-31
iShares Russell 2000 Growth 684380 0.84% 1180 0.17% 2018-06-21

Kenneth M. Bate Kenneth M. Bate is a businessperson who founded JSB-Partners LP and who has been the head of 6 different companies. Presently, he is Chairman for Catabasis Pharmaceuticals, Inc. and Chairman for Genocea Biosciences, Inc. Mr. Bate is also on the board of AVEO Pharmaceuticals, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc. In his past career Kenneth M. Bate occupied the position of Chief Executive Officer of Mpm Capital LLC, Chief Financial Officer at Biogen, Inc. and Chief Financial Officer, VP-Sales & Marketing at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Partner at JSB-Partners LP, Lead Independent Director at Cubist Pharmaceuticals LLC, President, Chief Executive Officer & Director at Archemix Corp., President, Chief Executive Officer & Director at NitroMed, Inc. and CFO & Head-Commercial Operations at Takeda Oncology Co. Kenneth M. Bate received an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania.
Michael John Higgins Michael John Higgins is Chairman for Voyager Therapeutics, Inc. Mr. Higgins is also on the board of 5 other companies. In his past career he occupied the position of Chief Operating Officer of Ironwood Pharmaceuticals, Inc., Chief Financial Officer of Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer for Procept, Inc. Michael John Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College.
Thomas Andrew Davis Currently, Thomas Andrew Davis holds the position of Chief Medical Officer for Genocea Biosciences, Inc. In the past Dr. Davis occupied the position of Chief Medical Officer & Executive Vice President at Celldex Therapeutics, Inc. and Chief Medical Officer & Senior Vice President of AVANT Immunotherapeutics, Inc. (a subsidiary of Celldex Therapeutics, Inc.), Chief Medical Officer & VP-Clinical Development at Celldex Research Corp., Chief Medical Officer of Gadeta BV, Chief Medical Officer of GenVec, Inc. and Senior Director-Clinical Science at Medarex, Inc. He received a doctorate and a graduate degree from Georgetown University and an undergraduate degree from The Johns Hopkins University.
William D. Clark William D. Clark founded Vanda Pharmaceuticals, Inc. Presently, he is President, Chief Executive Officer & Director at Genocea Biosciences, Inc. In the past Mr. Clark held the position of Principal at Care Capital LLC and Secretary, Chief Business Officer & Senior VP at Vanda Pharmaceuticals, Inc. He received an undergraduate degree from Harvard University and an MBA from The Wharton School of the University of Pennsylvania.
Michael John Higgins Michael John Higgins is Chairman for Voyager Therapeutics, Inc. Mr. Higgins is also on the board of 5 other companies. In his past career he occupied the position of Chief Operating Officer of Ironwood Pharmaceuticals, Inc., Chief Financial Officer of Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer for Procept, Inc. Michael John Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College.
William D. Clark Dr. Seth V. Hetherington, MD, is Chief Medical Officer at Genocea Biosciences, Inc. Dr. Hetherington was previously employed as SVP-Clinical & Regulatory Affairs by Neusentis, Inc., Chief Medical Officer & VP-Clinical Development by Inhibitex, Inc., Head-Clinical Program by GlaxoSmithKline, Inc., Head-Clinical Program by Glaxo Wellcome, Inc., and a Principal by University of North Carolina at Chapel Hill. He received his undergraduate degree from Yale University and a doctorate degree from the University of North Carolina at Chapel Hill.
Katrine S. Bosley Katrine S. Bosley is on the board of Galapagos NV, Biotechnology Innovation Organization, Genocea Biosciences, Inc. (former Chairman) and Massachusetts Eye & Ear Infirmary, Inc. In the past she was President & Chief Executive Officer of Editas Medicine, Inc., Director-Decision Support at Biogen, Inc., Chief Executive Officer of Avila Therapeutics, Inc., Vice President-Strategic Operations at Adnexus, President-Celgene Avilomics Research at Celgene LLC and Principal at Alkermes, Inc. She received an undergraduate degree from Cornell University.
Kenneth M. Bate Kenneth M. Bate is a businessperson who founded JSB-Partners LP and who has been the head of 6 different companies. Presently, he is Chairman for Catabasis Pharmaceuticals, Inc. and Chairman for Genocea Biosciences, Inc. Mr. Bate is also on the board of AVEO Pharmaceuticals, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc. In his past career Kenneth M. Bate occupied the position of Chief Executive Officer of Mpm Capital LLC, Chief Financial Officer at Biogen, Inc. and Chief Financial Officer, VP-Sales & Marketing at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Partner at JSB-Partners LP, Lead Independent Director at Cubist Pharmaceuticals LLC, President, Chief Executive Officer & Director at Archemix Corp., President, Chief Executive Officer & Director at NitroMed, Inc. and CFO & Head-Commercial Operations at Takeda Oncology Co. Kenneth M. Bate received an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania.
Katrine S. Bosley Ms. Katrine S. Bosley is a President, Chief Executive Officer & Director at Editas Medicine, Inc., a Chairman at Genocea Biosciences, Inc. and an Independent Non-Executive Director at Galapagos NV. She is on the Board of Directors at Editas Medicine, Inc., Galapagos NV and Biotechnology Innovation Organization. Ms. Bosley was previously employed as a President-Celgene Avilomics Research by Celgene LLC, a President & Chief Executive Officer by Avila Therapeutics, Inc., a Vice President-Business Development by Adnexus A Bristol-Myers Squibb R&D Co., a Principal by Alkermes, Inc., and a Director-Decision Support by Biogen, Inc. She also served on the board at CoCo Therapeutics Ltd. and Scholar Rock, Inc. She received her undergraduate degree from Cornell University.
George R. Siber George R. Siber holds the position of Chief Scientific Officer at Clearpath Vaccines Co. He is also on the board of Genocea Biosciences, Inc. (former Executive Chairman) and International Vaccine Institute. In the past Dr. Siber held the position of Chief Scientific Officer & Executive VP at Wyeth Corp., Associate Professor at Dana-Farber Cancer Institute, Inc. and Associate Professor at Harvard Medical School. George R. Siber received a doctorate from McGill University and an undergraduate degree from Bishop's University.
Ali Behbahani Currently, Ali Behbahani occupies the position of General Partner for NEA Management Co. LLC. Dr. Behbahani is also Partner at New Enterprise Associates LLC and on the board of 13 other companies. In the past he was Consultant at The Medicines Co., Analyst at Lehman Brothers Asset Management LLC and Venture Associate at Morgan Stanley Venture Partners. Dr. Behbahani received an undergraduate degree from Duke University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate from Perelman School of Medicine.
Jennifer LaVin Currently, Jennifer LaVin is Press Contact at Genocea Biosciences, Inc. Ms. LaVin previously occupied the position of Director-Investor Relations of Cubist Pharmaceuticals, Inc.
Jessica Baker Flechtner Currently, Jessica Baker Flechtner is Chief Scientific Officer of Genocea Biosciences, Inc. She is also Member of International Society for Biological Therapy of Cancer, Member of The American Association of Immunologists, Member of American Society for Microbiology, Member of Women in Bio, Inc., Member of President's Council of Cornell Women and Member of American Association for Cancer Research. In her past career Dr. Flechtner occupied the position of Principal at Mojave Therapeutics, Inc. Dr. Flechtner received an undergraduate degree and a doctorate from Cornell University.
Howard Mayer Dr. Howard Mayer, MD, is an Independent Director at Genocea Biosciences, Inc. and a Chief Medical Officer, Senior VP, Head-R&D at Shire Plc. He is on the Board of Directors at Entasis Therapeutics Holdings, Inc., Genocea Biosciences, Inc. and Melmark Charitable Foundation. Dr. Mayer was previously employed as a Chief Medical Officer by EMD Serono, Inc. and a Head-Clinical Development & Medical Affairs by Pfizer Inc. He also served on the board at Autism Speaks, Inc. He received his undergraduate degree from the University of Pennsylvania and a doctorate degree from Albert Einstein College of Medicine, Inc..
Pamela Carroll Pamela Carroll is Senior Vice President-Immuno-Oncology at Genocea Biosciences, Inc. In her past career she was Vice President-Oncology Scientific Innovation at Janssen Pharmaceuticals, Inc. and Head-Nutley Oncology Discovery Site at Roche Pharmaceuticals, Inc. Pamela Carroll received an undergraduate degree from St. Michael's College and a doctorate from Stony Brook University.
Ronald H. W. Cooper Presently, Ronald H. W. Cooper holds the position of President, Chief Executive Officer & Director at Albireo Pharma, Inc. and President, Chief Executive Officer & Director at Albireo AB (a subsidiary of Albireo Pharma, Inc.). He is also on the board of Genocea Biosciences, Inc. and Albireo Ltd. (former President, Chief Executive Officer & Director). In the past he was President-Europe at Bristol-Myers Squibb Co. He received an undergraduate degree from St. Francis Xavier University.
Diantha Duvall Diantha Duvall occupies the position of Chief Financial Officer of Genocea Biosciences, Inc. In the past Ms. Duvall occupied the position of Global Commercial Controller at Biogen, Inc. and Chief Accounting Officer, VP & Controller at Bioverativ, Inc. Ms. Duvall received an MBA from Northeastern University and a graduate degree from Colby College.
Narinder Singh Narinder Singh is Senior VP-Pharmaceutical Sciences & Manufacturing at Genocea Biosciences, Inc. and VP-Drug Product Development & Manufacturing at Momenta Pharmaceuticals, Inc. He received an undergraduate degree and a graduate degree from Indian Institute of Technology New Delhi, a graduate degree from the University of Houston and an MBA from UCLA Anderson School of Management.
Michael Alfieri Michael Alfieri is Chief Accounting Officer of Genocea Biosciences, Inc. In his past career Mr. Alfieri occupied the position of Vice President-Finance of Radius Health, Inc., Controller at Merrimack Pharmaceuticals, Inc. and Controller & Executive Director-Finance at Anika Therapeutics, Inc. He received an undergraduate degree and a graduate degree from Bentley University.
Derek M. Meisner Currently, Derek M. Meisner holds the position of Senior Vice President & General Counsel of Genocea Biosciences, Inc. In his past career Mr. Meisner occupied the position of Partner at K&L Gates LLP and General Counsel for Quantopian, Inc. He received an undergraduate degree from the University of Michigan and a graduate degree from American University Washington College of Law.
Girish Aakalu Girish Aakalu is Chief Business Officer at Genocea Biosciences, Inc. He received an undergraduate degree from The Johns Hopkins University and a doctorate from California Institute of Technology.
Sudhir Rao Sudhir Rao is Senior Director-Business Development at Genocea Biosciences, Inc.
Sudhir Rao Sudhir Rao is Senior Director-Business Development at Genocea Biosciences, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐